AbbVie slammed by FDA for improper handling of Humira death complaints: report

AbbVie
In a Form 483, the FDA cited AbbVie for inadequately processing its death complaints related to Humira. (AbbVie)

A number of AbbVie products coming out of its North Chicago, Illinois, manufacturing facility have been tied to death complaints, including its mammoth blockbuster Humira, and the FDA says the drugmaker has not done enough to investigate those complaints.

During an inspection at the plant late last year, FDA inspectors found that AbbVie had received five complaints tied to deaths after taking Humira and Venclexta. While the drugmaker reported those, it didn't go back and compile historical data about death complaints tied to drugs coming from the same lots. It turns out those lots had been tied to another 8 to 11 complaints each, the FDA noted in a Form 483 seen by STAT.

In a statement shared with FiercePharma, an AbbVie spokeswoman countered the FDA observation, saying the company “investigates all complaints where a death has occurred during the use of our products,” and that “written complaint procedures are in place to investigate, analyze and resolve complaints.” As for the observations at hand, she said AbbVie has responded “satisfactorily.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Humira, with worldwide sales of $18.4 billion in 2017, accounted for about 65% of AbbVie’s total revenues that year. As for Venclexta, the FDA just allowed it to be used in combination with Rituxan as a second-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of 17p deletion.

RELATED: AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024

The FDA also found AbbVie's procedures for handling death complaints for products made at the plant “inadequate.” For example, for Lupron, a product for prostate cancer and endometriosis, among others, no document showed that AbbVie evaluated complaints to see if there were other ones for nearby lot numbers or different strengths, or that it examined the reserve sample.

Moreover, the agency also warned AbbVie for not examining reserve samples at least once a year for evidence of deterioration, and for its failure to investigate drug batches manufactured close to a problematic one.

RELATED: FDA Form 483 shows Pfizer repeating same mistakes at troubled fill-finish plant

Last September, Pfizer’s Meridian Medical Technologies plant near St. Louis, Missouri, which makes EpiPen for Mylan, was dinged by an FDA warning letter for failing to thoroughly investigate hundreds of complaints about EpiPen failures during emergencies, some cases in which patients subsequently died. Around the time the agency was carrying out a reinspection of the plant that led to the warning letter, Mylan was recalling about 80,000 Pfizer-made epinephrine autoinjectors.

Another Pfizer fill-finish plant in Kansas was recently cited by a Form 483 with 10 observations, four of which were repeats of problems the FDA had previously observed, including insufficient examination of customer complaints to determine the cause.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.